mRNA-1189 / Moderna - LARVOL DELTA

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults (clinicaltrials.gov) - P1/2 | N=867 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Epstein-Barr Virus Infections • Infectious Disease

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants (clinicaltrials.gov) - P1 | N=474 | Recruiting | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Recruiting | N=354 ➔ 474

Enrollment change • Enrollment open • Epstein-Barr Virus Infections • Infectious Disease

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults (clinicaltrials.gov) - P1 | N=354 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Feb 2026 ➔ Jun 2027 | Trial primary completion date: Feb 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Epstein-Barr Virus Infections • Infectious Disease

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults (clinicaltrials.gov) - P1/2 | N=842 | Recruiting | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Recruiting | Phase classification: P1 ➔ P1/2 | N=422 ➔ 842 | Trial completion date: Jun 2025 ➔ Oct 2026 | Trial primary completion date: Jun 2025 ➔ Oct 2026

Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Epstein-Barr Virus Infections • Infectious Disease

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults (clinicaltrials.gov) - P1 | N=354 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Epstein-Barr Virus Infections • Infectious Disease

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults (clinicaltrials.gov) - P1 | N=422 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Epstein-Barr Virus Infections • Infectious Disease

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults (clinicaltrials.gov) - P1 | N=422 | Recruiting | Sponsor: ModernaTX, Inc. | N=272 ➔ 422 | Trial completion date: Jun 2023 ➔ Jun 2025 | Trial primary completion date: Jun 2023 ➔ Jun 2025

Enrollment change • Trial completion date • Trial primary completion date • Epstein-Barr Virus Infections • Infectious Disease

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults (clinicaltrials.gov) - P1 | N=500 | Recruiting | Sponsor: ModernaTX, Inc.

New P1 trial • Epstein-Barr Virus Infections • Infectious Disease

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-Year-Old Healthy Adults (clinicaltrials.gov) - P1; N=272; Recruiting; Sponsor: ModernaTX, Inc.

Clinical • New P1 trial • Epstein-Barr Virus Infections • Infectious Disease